Home
DSGN
DSGN News

Latest Design Therapeutics Inc. (DSGN) News on July 1, 2025

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

GlobeNewswire

a month ago

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

GlobeNewswire

a month ago

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

3 Penny Stocks With Market Caps As Low As $70M To Watch

Simply Wall St.

a month ago

3 Penny Stocks With Market Caps As Low As $70M To Watch

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

GlobeNewswire

2 months ago

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

GlobeNewswire

2 months ago

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

Design Therapeutics reports positive outcomes from trial of DT-168 eye drops

Clinical Trials Arena

2 months ago

Design Therapeutics reports positive outcomes from trial of DT-168 eye drops

MT Newswires

2 months ago

Top Premarket Gainers

MT Newswires

2 months ago

Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

GlobeNewswire

2 months ago

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

GlobeNewswire

2 months ago

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

April 2025's Promising Penny Stocks

Simply Wall St.

2 months ago

April 2025's Promising Penny Stocks

MT Newswires

2 months ago

Design Therapeutics Names Chris Storgard as Chief Medical Officer

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

GlobeNewswire

2 months ago

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

GlobeNewswire

2 months ago

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Design Therapeutics (DSGN) Upgraded to Buy: Here's Why

Zacks

4 months ago

Design Therapeutics (DSGN) Upgraded to Buy: Here's Why

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

4 months ago

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

GlobeNewswire

4 months ago

Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

US Penny Stocks To Watch In February 2025

Simply Wall St.

4 months ago

US Penny Stocks To Watch In February 2025

3 Promising US Penny Stocks With Market Caps Under $900M

Simply Wall St.

5 months ago

3 Promising US Penny Stocks With Market Caps Under $900M

MT Newswires

6 months ago

Top Premarket Decliners

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

GlobeNewswire

8 months ago

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

GlobeNewswire

8 months ago

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely

Simply Wall St.

8 months ago

We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely

Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock

Simply Wall St.

9 months ago

Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

GlobeNewswire

10 months ago

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet

Zacks

10 months ago

Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet

With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investors

Simply Wall St.

a year ago

With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investors

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

GlobeNewswire

a year ago

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

GuruFocus.com

a year ago

Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

GlobeNewswire

a year ago

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

MT Newswires

a year ago

--Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

GlobeNewswire

a year ago

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Independent Director of Design Therapeutics Picks Up 88% More Stock

Simply Wall St.

a year ago

Independent Director of Design Therapeutics Picks Up 88% More Stock

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Simply Wall St.

a year ago

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

a year ago

Q4 2023 Design Therapeutics Inc Earnings Call

GuruFocus.com

a year ago

Design Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline Progress

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

a year ago

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

GlobeNewswire

a year ago

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Organigram Completes First Shipment to Germany, Extending its International Reach

Business Wire

a year ago

Organigram Completes First Shipment to Germany, Extending its International Reach

Thomson Reuters StreetEvents

a year ago

Q4 2023 Bridgewater Bancshares Inc Earnings Call

Bridgewater Bancshares Inc (BWB) Reports Q4 Earnings Dip Amidst Market Challenges

GuruFocus.com

a year ago

Bridgewater Bancshares Inc (BWB) Reports Q4 Earnings Dip Amidst Market Challenges

Online Marketplace Stocks Q3 Teardown: Shutterstock (NYSE:SSTK) Vs The Rest

StockStory

a year ago

Online Marketplace Stocks Q3 Teardown: Shutterstock (NYSE:SSTK) Vs The Rest

Ares Dynamic Credit Allocation Fund Inc's Dividend Analysis

GuruFocus.com

a year ago

Ares Dynamic Credit Allocation Fund Inc's Dividend Analysis

Stitch Fix (SFIX) Fortifies With AI Amid Market Challenges

Zacks

a year ago

Stitch Fix (SFIX) Fortifies With AI Amid Market Challenges

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GlobeNewswire

a year ago

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Charles Brandes Adjusts Position in Graham Corp

GuruFocus.com

a year ago

Charles Brandes Adjusts Position in Graham Corp

The Zacks Analyst Blog Highlights JAKKS Pacific, Hooker Furniture, Netflix, Skillz and Acushnet

Zacks

a year ago

The Zacks Analyst Blog Highlights JAKKS Pacific, Hooker Furniture, Netflix, Skillz and Acushnet

Reasons to Retain Graco (GGG) Stock in Your Portfolio Now

Zacks

a year ago

Reasons to Retain Graco (GGG) Stock in Your Portfolio Now

5 Solid Stocks to Buy on a Solid Jump in Factory Orders

Zacks

a year ago

5 Solid Stocks to Buy on a Solid Jump in Factory Orders

HIVE Digital Provides Recap of Calendar Year 2023 Mining 3,260 Bitcoin

Newsfile

a year ago

HIVE Digital Provides Recap of Calendar Year 2023 Mining 3,260 Bitcoin

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire

2 years ago

CORRECTING and REPLACING Eaton Vance Declares Early Monthly Distributions and Special Distributions for Certain Eaton Vance Closed-End Funds

Perfect Corp (NYSE:PERF): The Vanguard Of Beauty And Fashion Tech Innovation That Helps Brands Drive Sales

ACCESSWIRE

2 years ago

Perfect Corp (NYSE:PERF): The Vanguard Of Beauty And Fashion Tech Innovation That Helps Brands Drive Sales

Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know

Zacks

2 years ago

Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know

Sachem Capital Corp. Announces Dividend of $0.11 per Share

GlobeNewswire

2 years ago

Sachem Capital Corp. Announces Dividend of $0.11 per Share

Barings Participation Investors Announces Increased Quarterly Cash Dividend of $0.35 Per Share

Business Wire

2 years ago

Barings Participation Investors Announces Increased Quarterly Cash Dividend of $0.35 Per Share

Strength Seen in First Commonwealth Financial (FCF): Can Its 5.5% Jump Turn into More Strength?

Zacks

2 years ago

Strength Seen in First Commonwealth Financial (FCF): Can Its 5.5% Jump Turn into More Strength?

Despite recent sales, Weyco Group, Inc. (NASDAQ:WEYS) insiders still hold the largest share with a 39% interest

Simply Wall St.

2 years ago

Despite recent sales, Weyco Group, Inc. (NASDAQ:WEYS) insiders still hold the largest share with a 39% interest

Tortoise Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Updates as of November 30, 2023, for TYG, NTG, TTP, NDP and TPZ

ACCESSWIRE

2 years ago

Tortoise Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Updates as of November 30, 2023, for TYG, NTG, TTP, NDP and TPZ

Virtus Convertible & Income Fund II Announces Quarterly Distribution: 5.500% Series A Cumulative Preferred Shares

Business Wire

2 years ago

Virtus Convertible & Income Fund II Announces Quarterly Distribution: 5.500% Series A Cumulative Preferred Shares

Positive Signs As Multiple Insiders Buy Design Therapeutics Stock

Simply Wall St.

2 years ago

Positive Signs As Multiple Insiders Buy Design Therapeutics Stock

Certain Virtus Closed-End Funds Announce Three Monthly Distributions: NCV, NCZ, CBH

Business Wire

2 years ago

Certain Virtus Closed-End Funds Announce Three Monthly Distributions: NCV, NCZ, CBH

GuruFocus.com

2 years ago

Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

GlobeNewswire

2 years ago

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Astria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate Developments

GuruFocus.com

2 years ago

Astria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate Developments

Fulcrum Therapeutics Inc (FULC) Reports Q3 2023 Financial Results and Business Highlights

GuruFocus.com

2 years ago

Fulcrum Therapeutics Inc (FULC) Reports Q3 2023 Financial Results and Business Highlights

Saba Capital Management, L.P. Increases Stake in ASA Gold And Precious Metals Ltd

GuruFocus.com

2 years ago

Saba Capital Management, L.P. Increases Stake in ASA Gold And Precious Metals Ltd

Cerus Corporation to Participate in Upcoming Investor Conferences

Business Wire

2 years ago

Cerus Corporation to Participate in Upcoming Investor Conferences

Share on Social Networks: